Novel psychoactive substances in young adults with and without psychiatric comorbidities.
about
Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practiceNPS: Medical Consequences Associated with Their IntakeNovel psychoactive substances: the pharmacology of stimulants and hallucinogens.Problematic Alcohol Use among University Students.Brief interventions implementation on alcohol from the European health systems perspective.Following "the Roots" of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries.Acute Effects of the Novel Psychoactive Drug 2C-B on EmotionsAccessibility and affordability of alcohol dependency medical care in serbia.The prevalence of novel psychoactive substances (NPS) use in non-clinical populations: a systematic review protocolPatterns of Substance Use Across the First Year of College and Associated Risk Factors.Can Google Searches Predict the Popularity and Harm of Psychoactive Agents?The Synergistic Impact of Excessive Alcohol Drinking and Cigarette Smoking upon Prospective Memory.Use of novel psychoactive substances by inpatients on general adult psychiatric wardsPsyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products.Drunkorexia: an emerging trend in young adults.Novel psychoactive substances (NPS) use in severe mental illness (SMI) patients: Potential changes in the phenomenology of psychiatric diseases.4,4'-Dimethylaminorex ("4,4'-DMAR"; "Serotoni") misuse: A Web-based study.1-cyclohexyl-x-methoxybenzene derivatives, novel psychoactive substances seized on the internet market. Synthesis and in vivo pharmacological studies in mice.Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter-observational study.A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.Is there any difference in patterns of use and psychiatric symptom status between injectors and non-injectors of mephedrone?A novel psychoactive substance poses a new challenge in the management of paranoid schizophreniaAn insight into the deep web; why it matters for addiction psychiatry?Substance-related psychopathology and aggressiveness in a nightlife holiday resort: Results from a pilot study in a psychiatric inpatient unit in Ibiza.Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies.Octodrine: New Questions and Challenges in Sport Supplements.Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives.
P2860
Q26800235-55FC69E3-16F4-4C63-A92A-DF697D298DE6Q28276182-BF679F5E-FE04-473B-89A2-944DEDF39BC4Q30251771-5A633E2E-0EF1-4840-994F-B58AC880EBB1Q33705043-2FC6894C-4B01-4036-BDA3-F01426B9D01EQ34488380-8A390CFF-17D3-4404-A371-4B991A835D30Q34504233-26167587-37A2-4D8B-BE34-F33B46B8FE32Q34674320-7A68DF58-A75B-45D5-A472-686176AE3BF0Q34911967-47199B79-A4A6-49A5-AC1D-310BE37321D6Q36200336-6B5BAA82-9534-4563-8B30-81C33CD7DE48Q36209103-964B2293-B4AC-4826-9A7F-05C3EC408472Q36674560-705C9175-DA72-4505-AC03-0B447427280AQ36840906-4A81ED06-DA29-4565-BB84-4568E12B4F74Q36920246-B3292269-23A2-443C-A031-F57620033F52Q38555624-699D33A8-6698-4C8E-9E84-89A37C3E6EFCQ38608674-5A0B7B93-C541-4473-B2B4-86868B419B0AQ38705404-422133B2-FCBE-4A12-889C-53EEB73FD953Q38705409-41D384FC-5286-4C1C-BE24-B618964555B8Q38705413-862D27D2-A9A0-4691-90C2-D0FFF7F86306Q38778976-0C6F1C20-A4E8-4483-B2F7-83ACF3FD45B7Q38796132-325BB856-B3AB-4F68-89DB-E4F97B122958Q40300253-3654522B-5F8D-44A3-90AF-EE6E1E0037C0Q40747227-BC9920B7-09B4-4585-A35E-1C0061DB43DCQ45881546-E7D2A6DE-DEBC-459C-B012-2404DA435757Q47726010-C4C3F719-05C4-449A-9A2B-D2051EB53E8DQ48301733-467AF384-4EFD-49C5-9ED8-6C95A289E0DAQ50027193-175391BC-FD0C-4A42-B510-801FD08EC1B4Q55080181-B24A320C-DC1C-4434-9C7B-C2AD2B594461
P2860
Novel psychoactive substances in young adults with and without psychiatric comorbidities.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Novel psychoactive substances in young adults with and without psychiatric comorbidities.
@ast
Novel psychoactive substances in young adults with and without psychiatric comorbidities.
@en
Novel psychoactive substances in young adults with and without psychiatric comorbidities.
@nl
type
label
Novel psychoactive substances in young adults with and without psychiatric comorbidities.
@ast
Novel psychoactive substances in young adults with and without psychiatric comorbidities.
@en
Novel psychoactive substances in young adults with and without psychiatric comorbidities.
@nl
prefLabel
Novel psychoactive substances in young adults with and without psychiatric comorbidities.
@ast
Novel psychoactive substances in young adults with and without psychiatric comorbidities.
@en
Novel psychoactive substances in young adults with and without psychiatric comorbidities.
@nl
P2093
P2860
P50
P356
P1476
Novel psychoactive substances in young adults with and without psychiatric comorbidities
@en
P2093
Giovanni Martinotti
Laura Bandini
Massimo di Giannantonio
Paola Ciambrone
Salvatore Calò
Tiziano Acciavatti
P2860
P304
P356
10.1155/2014/815424
P407
P50
P577
2014-07-15T00:00:00Z